- Home
- HERZ vs PASG Comparison
HERZ vs PASG Comparison
Compare HERZ & PASG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HERZ | PASG |
|---|---|---|
| Founded | N/A | 2017 |
| Country | United States | United States |
| Employees | N/A | 27 |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.7M | 19.2M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | HERZ | PASG |
|---|---|---|
| Price | $16.01 | $6.09 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | 12.3K | ★ 37.4K |
| Earning Date | N/A | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.62 | $0.35 |
| 52 Week High | $19.30 | $20.00 |
Technical Indicators
Market Signals| Indicator | HERZ | PASG |
|---|---|---|
| Relative Strength Index (RSI) | 40.09 | 58.31 |
| Support Level | $15.27 | $6.04 |
| Resistance Level | $16.39 | $8.94 |
| Average True Range (ATR) | 0.66 | 0.46 |
| MACD | -0.13 | 0.08 |
| Stochastic Oscillator | 12.66 | 96.62 |
Price Performance
Historical ComparisonAbout HERZ Herzfeld Credit Income Fund Inc.
Herzfeld Credit Income Fund Inc is a non-diversified, closed-end management investment company. Its primary investment objective is to maximize risk-adjusted total returns, and its secondary investment objective is to generate high current income.
About PASG Passage Bio Inc.
Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.